Rapidly emerging SARS-CoV-2 variants jeopardize antibody-based countermeasures.
Although cell culture experiments have demonstrated a loss of potency of several anti-spike …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused the global
COVID-19 pandemic. Rapidly spreading SARS-CoV-2 variants may jeopardize newly …

Prevention of viral escape and increased coverage against severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) variants of concern require therapeutic monoclonal …

The COVID-19 pandemic has had widespread effects across the globe, and its causative
agent, SARS-CoV-2, continues to spread. Effective interventions need to be developed to …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) B. 1.1. 7 and B. 1.351
variants were first identified in the United Kingdom and South Africa, respectively, and have …

The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) pandemic continues,
with devasting consequences for human lives and the global economy,. The discovery and …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused the global
COVID-19 pandemic infecting more than 106 million people and causing 2.3 million deaths …

Abstract The SARS-CoV-2 Omicron variant evades most currently approved neutralizing
antibodies (nAbs) and caused drastic decrease of plasma neutralizing activity elicited by …

Antibodies targeting the spike protein of severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) present a promising approach to combat the coronavirus disease 2019 …

Potent neutralizing monoclonal antibodies are one of the few agents currently available to
treat COVID-19. SARS-CoV-2 variants of concern (VOCs) that carry multiple mutations in the …